In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Holding AG

http://www.roche.com

Latest From Roche Holding AG

US Drug Shortages Aid Aurobindo’s Q4 Growth, Decentralized Trials On For Xolair Biosimilar

Drug shortages, stable prices and a demand recovery in the US helped drive Aurobindo’s growth in Q4. Meanwhile, the company is developing a biosimilar to Roche/Novartis’s multi-billion product Xolair, as predicted by Scrip earlier. Use of decentralized mode for its Phase III trials is a notable aspect

Commercial Sales & Earnings

Japan Eyes Cutting Reimbursement For COVID-19 Drugs

Japan will end full reimbursement coverage for COVID-19 therapeutic drugs from October, after downgrading the status of the virus to the same level as seasonal flu in early May. As authorities discuss the possible coverage reduction, a larger than usual price cut may also be applied to Shionogi's oral COVID antiviral Xocova.

Japan Pricing Debate

Pfizer’s Marstacimab Wins In Phase III, But Caution On Market Position, Clotting Remain

The drug showed efficacy in hemophilia A and B with no sign of clots, an issue that historically has dogged anticoagulation agents, but it remains unclear whether that advantage will hold.

Clinical Trials Blood & Coagulation Disorders

Big Pharma Companies Have Higher US FDA Approval Percentage Than Everybody Else

Almost 80% of novel agent submissions from the biggest companies were approved in recent years, compared with a 60% approval rate for the rest of the industry, according to a Pink Sheet analysis of FDA approval decisions since 2021.

US FDA Performance Tracker Drug Review
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Other Names / Subsidiaries
    • Adheron Therapeutics
    • Anadys Pharmaceuticals, Inc.
    • Ariosa Diagnostics
    • Arius Research, Inc.
    • Boehringer Mannheim
    • CAPP Medical
    • Chugai Pharmaceutical Co., Ltd.
    • Dutalys GmbH
    • Flatiron Health
    • Foundation Medicine
    • GenMark Diagnostics, Inc.
    • Genentech Inc.
    • GeneWEAVE BioSciences, Inc.
    • Genia Technologies, Inc.
    • GlycArt Biotechnology
    • Hoffmann-La Roche
    • Inflazome Ltd.
    • Ignyta, Inc. (RXDX) (Actagene Oncology, Inc
    • NexDx, Inc.)
    • Inception 5
    • InterMune, Inc.
    • Inflazome Ltd.
    • IQuum, Inc.
    • Jecure Therapeutics
    • Kapa Biosystems, Inc.
    • Marcadia Biotech, Inc.
    • Medingo Ltd.
    • Memory Pharmaceuticals Corporation
    • mtm laboratories AG
    • Piramed Pharma
    • Santaris Pharma A/S
    • Seragon Pharmaceuticals
    • Signature Diagnostics AG
    • Stratos Genomics
    • Syntex Corporation
    • Tanox, Inc.
    • Tensha Therapeutics, Trophos SA
    • Ventana Medical Systems, Inc.
    • Viewics, Inc.
UsernamePublicRestriction

Register